Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

PURPOSE To review the available evidence of chemoembolization for unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS Computerized bibliographic searches with MEDLINE and CANCERLIT databases from 1980 through 2000 were supplemented with manual searches, with the keywords "hepatocellular carcinoma," "liver cell carcinoma," "randomized controlled trial [RCT]," and "chemoembolization." Studies were included if patients with unresectable HCC were enrolled and if they were RCTs in which chemoembolization was compared with nonactive treatment (five RCTs) or if different transarterial modalities of therapy (13 RCTs) were compared. Data were extracted from each RCT according to the intention-to-treat method. Five of the RCTs with a nonactive treatment arm were combined by using the random-effects model, whereas all 18 RCTs were pooled from meta-regression analysis. RESULTS Chemoembolization significantly reduced the overall 2-year mortality rate (odds ratio, 0.54; 95% CI: 0.33, 0.89; P =.015) compared with nonactive treatment. Analysis of comparative RCTs helped to predict that overall mortality was significantly lower in patients treated with transarterial embolization (TAE) than in those treated with transarterial chemotherapy (odds ratio, 0.72; 95% CI: 0.53, 0.98; P =.039) and that there is no evidence that transarterial chemoembolization is more effective than TAE (odds ratio, 1.007; 95% CI: 0.79, 1.27; P =.95), which suggests that the addition of an anticancer drug did not improve the therapeutic benefit. CONCLUSION In patients with unresectable HCC, chemoembolization significantly improved the overall 2-year survival compared with nonactive treatment, but the magnitude of the benefit is relatively small.

[1]  Y. Yamashita,et al.  Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation , 1993, Abdominal Imaging.

[2]  M. Kusano,et al.  Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison of L-TAE with Farmorubicin and L-TAE with Adriamycin (second cooperative study) , 2004, Cancer Chemotherapy and Pharmacology.

[3]  P. Rissanen,et al.  Intra‐arterial and Intravenous Use of 4′ Epidoxorubicin Combined with 5‐Fluorouracil in Primary Hepatocellular Carcinoma: A Randomized Comparison , 1992, American journal of clinical oncology.

[4]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[5]  J. Bruix,et al.  Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution , 1998, Hepatology.

[6]  J. Pignon,et al.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. , 1998, Journal of hepatology.

[7]  M. Kusano,et al.  Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison between L-TAE with Farmorubicin and L-TAE with Adriamycin: preliminary results (second cooperative study) , 2004, Cancer Chemotherapy and Pharmacology.

[8]  J. Bruix,et al.  Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC) , 2001 .

[9]  C. Bartolozzi,et al.  Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. , 1995, Radiology.

[10]  K. Stokes,et al.  Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization , 1993, Cancer.

[11]  M. Kusano,et al.  Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study) , 2004, Cancer Chemotherapy and Pharmacology.

[12]  A. Konstantinidou,et al.  Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. , 1995, Anticancer research.

[13]  Y. Yamashita,et al.  Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. , 1995, Radiology.

[14]  D. Guyader,et al.  Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  I. Lauder,et al.  Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience , 2000, Hepatology.

[16]  Chien-Fang Yang,et al.  Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study , 1994, Cancer.

[17]  J. Bruix,et al.  Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.

[18]  K. Chayama,et al.  A Prospective Randomized Evaluation of a Compound of Tegafur and Uracil as an Adjuvant Chemotherapy for Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization , 1995, American journal of clinical oncology.

[19]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[20]  Y. Yamashita,et al.  Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion , 1991, Cancer.

[21]  G. Dusheiko,et al.  Epirubicin‐lipiodol chemotherapy versus 131iodine‐lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma , 1995, Cancer.

[22]  S. Kawata,et al.  Interleukin‐6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor , 1994, Cancer.

[23]  O. Ernst,et al.  Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. , 1999, AJR. American journal of roentgenology.

[24]  A. Roche,et al.  A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. , 1990, Journal of hepatology.

[25]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[26]  K. Chayama,et al.  A prospective randomized administration of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. , 1997, American journal of clinical oncology.

[27]  S. Sharp,et al.  Explaining heterogeneity in meta-analysis: a comparison of methods. , 1999 .

[28]  M. Kusano,et al.  Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. , 1997, Seminars in oncology.

[29]  D. Guyader,et al.  Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma , 1997, Hepatology.

[30]  J. Uchino,et al.  Adjuvant Chemoimmunotherapy for Hepatocellular Carcinoma Patients: Adriamycin, Interleukin‐2, and Lymphokine‐Activated Killer Cells Versus , 1995, American journal of clinical oncology.

[31]  V. Torri,et al.  Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. , 1989, JAMA.

[32]  Seishiro Watanabe,et al.  Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma , 2004, Cancer Chemotherapy and Pharmacology.

[33]  S L Normand,et al.  Meta-analysis: formulating, evaluating, combining, and reporting. , 1999, Statistics in medicine.

[34]  Y. Liaw,et al.  Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. , 1988, Gastroenterology.

[35]  R. Myers.  Meta-analysis of transarterial embolization in patients with unresectable hepatocellular carcinoma. , 2003, Radiology.

[36]  S. Peng,et al.  Lipiodolization with or without gelatin sponge in hepatic arterial chemoembolization for hepatocellular carcinoma. , 1994, Chinese medical journal.

[37]  S. Beningfield,et al.  Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. , 1993, Gut.

[38]  M. Egger,et al.  The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.

[39]  W. M. Lam,et al.  A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. , 2000, Journal of hepatology.

[40]  J. Ioannidis,et al.  Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.

[41]  O. Matsui,et al.  Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma , 1994, Hepatology.

[42]  F. P'eng,et al.  Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal , 1995, The British journal of surgery.

[43]  E. Lai,et al.  Treatment of unresectable hepatocellular carcinoma : Results of a randomized controlled trial , 1986, World journal of surgery.

[44]  Bernard,et al.  Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis? , 1998, Alimentary pharmacology & therapeutics.

[45]  Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection , 2004, Cancer Chemotherapy and Pharmacology.

[46]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[47]  M. Tatsuta,et al.  Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. , 1989, Gastroenterology.

[48]  M. Ebara,et al.  A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma , 2004, Cancer Chemotherapy and Pharmacology.